Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS 
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics Q2 Earnings Call Highlights
Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027.
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.
Kymera's CEO Sold $6 Million in Stock After a 170% Run
According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insider's direct common stock holdings by 7%, leaving a residual direct position of 667,000 shares.
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)
Kymera Therapeutics (KYMR) is upgraded to Buy, driven by strong pipeline progress and a robust $1.5bn cash position. KT-621, an oral STAT6 degrader for atopic dermatitis, has accelerated Phase 2b timelines with topline data now expected by year-end 2026. KT-621's oral administration and promising early efficacy/safety data position KYMR to challenge injectable incumbents in a multi-billion dollar market.
Kymera: Building Toward A Defining 2H26 Moment
Kymera Therapeutics is rated Buy ahead of the 2H26 KT-621 Phase 2b readout, seen as a key inflection point. KT-621, a first-in-class oral STAT6 degrader, targets large, expanding markets in atopic dermatitis and other type 2 inflammatory diseases. Rapid trial enrollment, a strong balance sheet ($1.55B cash), and external validation position KYMR for potential high-value partnerships and lifecycle expansion.
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
